Lansoprazol Mabo (Lansoprazole)

Lansoprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme, also known as the gastric proton pump, in the parietal cells of the stomach. This blockade stops the final step of acid secretion, leading to a sustained reduction in gastric acidity and allowing damaged mucosal tissue to heal.

The appropriate dose of Lansoprazol Mabo is determined by the prescribing clinician based on the specific indication, patient age, renal and hepatic function, and other clinical factors. Patients should follow the dosage instructions provided by their healthcare professional and the product label.

Safety data for lansoprazole during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will assess individual circumstances before prescribing it to pregnant or nursing women.

To order Lansoprazol Mabo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details, and any necessary import documentation.

Lansoprazol Mabo belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, its efficacy and safety profile are comparable, though individual response and drug‑interaction potential may vary.

Lansoprazol Mabo should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain its stability.

Lansoprazol Mabo is taken orally, usually as a tablet or capsule, with a glass of water. It is generally recommended to swallow the dose whole and not to crush or chew it, unless the product label specifies otherwise.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridium difficile‑associated diarrhea, liver enzyme abnormalities, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms such as rash, difficulty breathing, persistent diarrhea, or jaundice.

Lansoprazol Mabo should be avoided in individuals with known hypersensitivity to lansoprazole or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, those taking medications that require an acidic environment for absorption, and patients with a history of certain serious skin reactions.